BioSpace News Archive

AbbVie Tops Doctor Ranking of Immunology Companies, Handily Beating Pfizer and J&J

Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, according to a new survey of doctors by ZoomRx.

April 22, 2024
·
2 min read
·
Tristan Manalac
Business

Boehringer, Ochre Bio Team in Potential $1B Deal to Develop Regenerative Liver Drugs

Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.

April 22, 2024
·
2 min read
·
Nick Paul Taylor
Biotech Bay

BMS Taps Cellares in $380M CAR T Cell Therapy Manufacturing Agreement

Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.

April 22, 2024
·
2 min read
·
Tyler Patchen
Policy

Biosimilar Sales Up as Insurers Begin Dropping Humira Coverage

Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.

April 22, 2024
·
4 min read
·
Mollie Barnes
Drug Development

AbbVie, NeuroDerm Heat Up Levodopa Competition with New Data at AAN24

As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.

April 22, 2024
·
2 min read
·
Tristan Manalac
Policy

CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices

Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.

April 22, 2024
·
2 min read
·
Tristan Manalac
Business

Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases

Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.

April 22, 2024
·
2 min read
·
Tristan Manalac
Angle PLC Announces US and EU Patents for Innovative CellKeep(TM) Slide

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology, is pleased to announce that the European Patent Office has granted a European Patent for its innovative CellKeep™ slide.

April 22, 2024
·
4 min read
Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Immunovia announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study.

April 22, 2024
·
4 min read
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, provided an update on the clinical development of its lead asset, rupitasertib, a selective oral inhibitor of S6K and AKT1/AKT3.

April 22, 2024
·
3 min read